Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 10,900 Shares of Stock

Apogee Therapeutics Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 10,900 shares of the business’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $75.00, for a total value of $817,500.00. Following the completion of the sale, the insider owned 271,108 shares in the company, valued at $20,333,100. This represents a 3.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, November 5th, Carl Dambkowski sold 10,785 shares of Apogee Therapeutics stock. The shares were sold at an average price of $55.07, for a total value of $593,929.95.
• On Wednesday, October 1st, Carl Dambkowski sold 5,110 shares of Apogee Therapeutics stock. The stock was sold at an average price of $39.80, for a total transaction of $203,378.00.

Apogee Therapeutics Stock Performance

Shares of APGE opened at $76.75 on Friday. The company’s 50-day simple moving average is $57.59 and its 200-day simple moving average is $45.43. Apogee Therapeutics Inc. has a 1 year low of $26.20 and a 1 year high of $77.09. The stock has a market capitalization of $5.24 billion, a PE ratio of -17.52 and a beta of 1.41.

Apogee Therapeutics (NASDAQ:APGE) last announced its earnings results on Monday, November 10th. The company reported ($1.11) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.03. On average, sell-side analysts predict that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current year.

Institutional Investors Weigh In On Apogee Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Invesco Ltd. increased its stake in Apogee Therapeutics by 14.4% in the first quarter. Invesco Ltd. now owns 24,310 shares of the company’s stock valued at $908,000 after purchasing an additional 3,054 shares during the last quarter. Nuveen LLC acquired a new position in shares of Apogee Therapeutics in the 1st quarter valued at $4,142,000. Brooklyn Investment Group acquired a new position in shares of Apogee Therapeutics in the 1st quarter valued at $42,000. Wellington Management Group LLP grew its position in shares of Apogee Therapeutics by 21.4% in the 1st quarter. Wellington Management Group LLP now owns 5,485,754 shares of the company’s stock valued at $204,948,000 after buying an additional 968,391 shares during the last quarter. Finally, AlphaQuest LLC acquired a new stake in Apogee Therapeutics during the 1st quarter worth $43,000. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on APGE shares. Wedbush reiterated an “outperform” rating and issued a $90.00 price objective on shares of Apogee Therapeutics in a research note on Monday, August 11th. Craig Hallum began coverage on Apogee Therapeutics in a report on Monday, November 3rd. They set a “buy” rating and a $109.00 price target on the stock. Bank of America lifted their price objective on Apogee Therapeutics from $78.00 to $87.00 and gave the company a “buy” rating in a research note on Thursday, August 28th. Mizuho began coverage on shares of Apogee Therapeutics in a research note on Tuesday, October 21st. They set an “outperform” rating and a $105.00 target price on the stock. Finally, Citigroup reaffirmed a “buy” rating on shares of Apogee Therapeutics in a report on Thursday, August 28th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.38.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.